HRP20231276T1 - Inhibitor egfr-a za liječenje raka - Google Patents

Inhibitor egfr-a za liječenje raka Download PDF

Info

Publication number
HRP20231276T1
HRP20231276T1 HRP20231276TT HRP20231276T HRP20231276T1 HR P20231276 T1 HRP20231276 T1 HR P20231276T1 HR P20231276T T HRP20231276T T HR P20231276TT HR P20231276 T HRP20231276 T HR P20231276T HR P20231276 T1 HRP20231276 T1 HR P20231276T1
Authority
HR
Croatia
Prior art keywords
compound
treatment
cancer
formula
egfr inhibitor
Prior art date
Application number
HRP20231276TT
Other languages
English (en)
Inventor
Cosimo Dolente
Annick Goergler
David Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Ulrike Obst Sander
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20231276T1 publication Critical patent/HRP20231276T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Claims (7)

1. Spoj, naznačen time, da je predstavljen formulom (I) [image] (I) ili njegove farmaceutski prihvatljive soli.
2. Spoj formule (I) prema patentnom zahtjevu 1, naznačen time, da je spoj sljedeći [image] .
3. Spoj formule (I) prema patentnom zahtjevu 1 ili 2, naznačen time, da je spoj 2-[4,7-dikloro-6-(4-morfolinofenil)indazol-2-il]-2-[(6R)-6-fluoro-6,7-dihidro-5H-pirolo[1,2-c]imidazol-1-il]-N-tiazol-2-il-acetamid.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je za upotrebu kao terapeutski aktivna tvar.
5. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i terapeutski inertni nosač.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je za primjenu u liječenju ili profilaksi raka.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je za primjenu u liječenju ili profilaksi raka pluća nemalih stanica.
HRP20231276TT 2019-06-21 2020-06-19 Inhibitor egfr-a za liječenje raka HRP20231276T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19181754 2019-06-21
PCT/EP2020/067076 WO2020254562A1 (en) 2019-06-21 2020-06-19 Egfr inhibitor for the treatment of cancer
EP20734871.5A EP3986897B1 (en) 2019-06-21 2020-06-19 Egfr inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
HRP20231276T1 true HRP20231276T1 (hr) 2024-02-02

Family

ID=67139601

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231276TT HRP20231276T1 (hr) 2019-06-21 2020-06-19 Inhibitor egfr-a za liječenje raka

Country Status (28)

Country Link
US (4) US20220315592A1 (hr)
EP (4) EP3986895B1 (hr)
JP (4) JP2022537191A (hr)
KR (1) KR20220024105A (hr)
CN (4) CN113993873A (hr)
AR (4) AR119210A1 (hr)
AU (1) AU2020295703A1 (hr)
BR (1) BR112021025445B1 (hr)
CA (1) CA3140485A1 (hr)
CL (1) CL2021003408A1 (hr)
CO (1) CO2021017173A2 (hr)
CR (1) CR20210624A (hr)
DK (1) DK3986897T3 (hr)
ES (1) ES2961187T3 (hr)
FI (1) FI3986897T3 (hr)
HR (1) HRP20231276T1 (hr)
HU (1) HUE063676T2 (hr)
IL (1) IL288522A (hr)
LT (1) LT3986897T (hr)
MA (1) MA56508B1 (hr)
MX (1) MX2021015464A (hr)
PE (1) PE20220576A1 (hr)
PL (1) PL3986897T3 (hr)
PT (1) PT3986897T (hr)
RS (1) RS64720B1 (hr)
SI (1) SI3986897T1 (hr)
TW (4) TW202115072A (hr)
WO (4) WO2020254568A1 (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217924A1 (en) * 2022-05-13 2023-11-16 F. Hoffmann-La Roche Ag Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer
WO2023217923A1 (en) * 2022-05-13 2023-11-16 F. Hoffmann-La Roche Ag New indazole derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
US20110212078A1 (en) 2008-06-25 2011-09-01 Reddy Panduranga Adulla P Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
JP6639497B2 (ja) * 2014-11-10 2020-02-05 ジェネンテック， インコーポレイテッド ブロモドメインインヒビターおよびその使用
CN107848964B (zh) 2015-05-14 2021-03-19 威斯塔解剖学和生物学研究所 Ebna1抑制剂和使用其的方法
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
AR113299A1 (es) * 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
WO2019046668A1 (en) * 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
KR20210025535A (ko) * 2018-06-29 2021-03-09 에프. 호프만-라 로슈 아게 화합물

Also Published As

Publication number Publication date
EP3986897A1 (en) 2022-04-27
MA56508A (fr) 2022-04-27
FI3986897T3 (fi) 2023-10-20
TW202115053A (zh) 2021-04-16
EP3986898B1 (en) 2023-03-15
PE20220576A1 (es) 2022-04-20
TW202115074A (zh) 2021-04-16
WO2020254565A1 (en) 2020-12-24
JP2022537769A (ja) 2022-08-29
LT3986897T (lt) 2023-11-10
WO2020254562A1 (en) 2020-12-24
EP3986898A1 (en) 2022-04-27
AU2020295703A1 (en) 2022-01-06
CN113993872A (zh) 2022-01-28
TW202115072A (zh) 2021-04-16
TW202115071A (zh) 2021-04-16
US20220315593A1 (en) 2022-10-06
JP2022537191A (ja) 2022-08-24
CN113993873A (zh) 2022-01-28
US20220135571A1 (en) 2022-05-05
AR119210A1 (es) 2021-12-01
CO2021017173A2 (es) 2022-01-17
PT3986897T (pt) 2023-10-23
SI3986897T1 (sl) 2023-12-29
KR20220024105A (ko) 2022-03-03
CN113966335A (zh) 2022-01-21
RS64720B1 (sr) 2023-11-30
CA3140485A1 (en) 2020-12-24
AR119209A1 (es) 2021-12-01
WO2020254568A1 (en) 2020-12-24
ES2961187T3 (es) 2024-03-08
US20220315592A1 (en) 2022-10-06
WO2020254572A1 (en) 2020-12-24
CN114008049A (zh) 2022-02-01
JP2022538055A (ja) 2022-08-31
MA56508B1 (fr) 2023-11-30
BR112021025445A2 (pt) 2022-02-01
JP2022538403A (ja) 2022-09-02
MX2021015464A (es) 2022-01-24
AR119208A1 (es) 2021-12-01
DK3986897T3 (da) 2023-10-30
EP3986895A1 (en) 2022-04-27
EP3986897B1 (en) 2023-08-30
BR112021025445B1 (pt) 2024-02-27
IL288522A (en) 2022-01-01
CR20210624A (es) 2022-02-14
PL3986897T3 (pl) 2024-01-22
EP3986895B1 (en) 2023-03-15
HUE063676T2 (hu) 2024-01-28
CL2021003408A1 (es) 2022-10-14
AR119206A1 (es) 2021-12-01
EP3986896B1 (en) 2023-03-15
US20230054473A1 (en) 2023-02-23
EP3986896A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
NZ766835A (en) Pharmaceutical compounds
EP2477987B1 (en) Modulators of toll-like receptors
MX2020006399A (es) Derivados de sulfonil urea.
NZ601754A (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2020001218A (es) Inhibidores selectivos de inflamasoma nlrp3.
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
EA201290237A1 (ru) Киназные ингибиторы
PH12020551639A1 (en) Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
PE20181888A1 (es) Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
HRP20221495T1 (hr) Farmaceutske kompozicije koje sadrže derivate imidazotiadiazola i imidazopiridazina kao inhibitore proteazom aktiviranih receptora 4 (par4) za liječenje agregacije trombocita
BR112013014184A2 (pt) compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
PH12020551638A1 (en) Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
HRP20231276T1 (hr) Inhibitor egfr-a za liječenje raka
MX2015012091A (es) Derivados de 2-((4-amino-3-(3-fluoro-5-hidroxifenil)-1h-pirazolo[3 ,4-d]pirimidin-1-il)metil)-3-(2-(trifluorometil)bencil)quinazolin -4(3h)-ona y su uso como inhibidores de fosfoinositida 3-quinasa.
HRP20160495T1 (hr) Morfolinilbenzotriazini za uporabu u terapiji raka
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
IL279800B2 (en) Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use
HRP20150030T1 (hr) Derivati pirazolokinolina kao inhibitori dna-pk
NZ730189A (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.